Financial results for the period ended June 30, 2026
As filed · Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended June 30, 2026.
What happened
FactEris Lifesciences Ltd. announced the outcome of its Board meeting held on July 29, 2026, where the Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also re-appointed M/s Kiran J. Mehta & Co. as the Cost Auditors for the financial year 2026-27. The filing includes a copy of the financial results and the limited review report, which is free from any qualifications.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
WithdrawnWith an EBIDTA of Rs. 180-200 cr.
Our International Business is well on its way to achieve Rs. 1,000 cr. revenue by 2029/ 2030
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- We see an EBIDTA potential of at least Rs. 50 cr. p.a. from the additional market opportunity (management committed by FY27)
- VE A NET-DEBT-TO-EBIDTA RATIO OF < 1.5x BY DEC 2026 (management committed by Q4 FY26)
Evidence
- Outcome of Board Meeting(opens the original filing in a new tab)
- Earlier statement · FY27
- Latest statement · FY27
- Earlier statement · FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%